Flow cytometry confirmed that only TriBAFF/CD3/ABDCon eliminated both tumor populations by day 20 of the experiment, whereas blinatumomab treatment was ineffective because of the emergence of CD19-KO tumors (Figs. 6D and S13A). The gene discussed is CD19; the disease is neoplasm.